Cancer Immunotherapy

Engineering the immune response to "self" for effective cancer immunotherapy
Shi Zhong, Karolina Malecek, Duane Moogk, Laura A Johnson, Zhiya Yu, Arsen Grigoryan, Eleazar Vega-Saenz de Miera, Farbod Darvishian, Wei Jun Gu, Katelyn McGary, Kevin Huang, Joshua Boyer, Emily Corse, Shao Yongzhao, Steven A Rosenberg, Nicholas P Restifo, Timothy Cardozo, Alan Frey, Iman Osman, Michelle Krogsgaard

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P22; DOI: 10.1186/2051-1426-2-S3-P22
Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy
Yuki Sato, Ramjay Vatsan, Bharat H Joshi, Syed R Husain, Raj K Puri

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P58; DOI: 10.1186/2051-1426-2-S3-P58
Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
Jing Li, Robert L Ferris

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P220; DOI: 10.1186/2051-1426-2-S3-P220
Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
S Carolina Berger, Daniel Sommermeyer, Michael Hudecek, Michael Berger, Ashwini Balakrishnan, Paulina Paskiewicz, Paula Kosasih, Christoph Rader, Stanley Riddell

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P3; DOI: 10.1186/2051-1426-2-S3-P3
Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study
Uwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, Florian Schenck, Katharina C Kähler, Volkmar Jacobi, Klaus Witthohn, Hans Lentzen, Peter Mohr

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 27; DOI: 10.1186/s40425-014-0027-z
S9. Proffered paper: Identification of novel immune checkpoints as targets for cancer immunotherapy
G Cojocaru, G Rotman, O Levy, A Toporik, L Dassa, I Vaknin, S Sameah-Greenwald, I Barbiro, E Neria, Z Levine

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) I5; DOI: 10.1186/2051-1426-2-S2-I5
P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
S Jallad, P Thomas, M Newport, F Kern

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P32; DOI: 10.1186/2051-1426-2-S2-P32
DCVax^®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress
Vivek Subbiah, Ravi Murthy, Chitra Hosing, Indresh Kaur, Gerald Falchook, Marnix Bosch

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P238; DOI: 10.1186/2051-1426-1-S1-P238
Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
Catja Freiburghaus, Sissela Broos, Linda C Sandin, Thomas H Tötterman, Takami Akagi, Mitsuru Akashi, Carl Borrebaeck, Peter Ellmark, Malin Lindstedt

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P128; DOI: 10.1186/2051-1426-1-S1-P128
Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome
Debraj GuhaThakurta, Li-Qun Fan, Tuyen Vu, Nadeem A Sheikh, James B Trager

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P101; DOI: 10.1186/2051-1426-1-S1-P101

Main menu

Cancer Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cancer Immunotherapy

Pages